drugset / Trial / NCT03361436

Eribulin and Radiation Therapy in Treating Patients With Retroperitoneal Liposarcoma That Can Be Removed by Surgery

NCT03361436

NaSingle-groupOpen-labelTreatment

Summary

This phase Ib trials studies the side effects and best dose of eribulin mesylate when given together with radiation therapy in treating patients with retroperitoneal liposarcoma that can be removed by surgery. Drugs used in chemotherapy, such as eribulin mesylate, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Giving chemotherapy with radiation therapy may kill more tumor cells.

Timeline

Start
2018-03-19
Primary completion
2023-02-14
Completion
2033-04-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Eribulin Small molecule Intravenous